Tumours of unknown primary: The role of immunohistochemistry;Tumeurs sans primitif connu: Place de l'immunohistochimie

Oncologie

Volumn 6, Issue 4, 2004, Pages 252-255

  Belleannee G ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Carcinoma of unknown primary; Immunohistochemistry; Metastastic Carcinoma

Indexed keywords

CALCITONIN; CALRETININ; CD34 ANTIGEN; CD45 ANTIGEN; CHROMOGRANIN; CYTOKERATIN; GLUCAGON; HORMONE RECEPTOR; INHIBIN; INSULIN; MELAN A; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; STEM CELL FACTOR; SYNAPTOPHYSIN; THYROGLOBULIN; TUMOR ANTIGEN;

ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CARCINOMA; COLON CARCINOMA; ENDOCRINE TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESOTHELIOMA; METASTASIS; OVARY CARCINOMA; PANCREAS CARCINOMA; PROSTATE CARCINOMA; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; THYROID CARCINOMA; TUMOR BIOPSY; TUMOR NECROSIS;

EID: 4043130208     PISSN: 12923818     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Abbruzzese IL, Abbruzzese MC, Hess KR, et al. (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12: 1272-80
2. Arber JM, Arber DA, Jenkins KA, Battifora H (1996) Effet of decalcification and fixation in paraffin section immunohistochemistry. Appl Immunohistochem 4: 241-8
3. Ayoub JP, Hess KR, Abbruzzese MC, et al. (1998) Unknown primary tumors metastastic to liver. J Clin Pathol 16: 2105-12
4. Bacchi CE, Garcia RL, Gown AM (1997) Immunolocalization of estrogen and progesterone receptors in neuroendocrine tumors of lung, skin, gastrointestinal and female genital tracts. Appl Immunohistochem 5: 17-22
5. Brown RW, Campagna LB, Dunn JK, Cagle PT (1997) Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. Am J Clin Pathol 107: 12-9
6. Bugat R, Bataillard A, Lesimple T, et al. et FNCLCC, CRLCC (2002, 2003) Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site. Bull Cancer 89: 869-75 and Br J Cancer 89: S59-66
7. Bugat R, Bataillard A, Lesimple T, et al. et FNCLCC, CRLCC (2002, 2003) Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site. Bull Cancer 89: 869-75 and Br J Cancer 89: S59-66
8. Chan JKC (2000) Advances in immunohistochemistry: impact on surgical pathology practice. Semin Diagn Pathol 17: 170-7
9. Culine S, Kramar A, Saghatchian M, et al. and French Study Group on Carcinomas of Unknown Primary (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20: 4679-83
10. De Young BR, Wick MR (2000) Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Sem Diagn Pathol 17: 184-93
11. Fletcher CDM (2000) Introduction. In: Fletcher CDM. Diagnostic histopathology of tumors. Churchill Livingstone, pp. 1-5
12. Hainsworth JD, Wright EP, Johnson DH, et al. (1991) Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol 19: 1931-8
13. Hammar SP (1998) Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 29: 1393-402
14. Harach H, Franssila K (1988) Thyroglobulin immunostaining in follicular thyroid carcinoma: relationship to the degree of differentiation and cell type. Histopathology 13: 43-54
15. Kaufmann O, Kother S, Dietel M (1998) Use of antibodies against estrogen and progesterone receptors to identify metastatic breast and ovarian carcinomas by conventional immunohistochemical and tyramide signal amplification methods. Mod Pathol 11 (4): 357-63
16. Lagendijk JH, Mullink H, Van Diest PJ,et al. (1998) Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 29: 491-7
17. Lenzi R, Hess KR, Abbruzzese MC, et al. (1997) Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 15: 2056-66
18. Leroy X, Copin MC, Boman F, Gosselin B. (1998) Les cyto-kératines 7 et 20: aide au typage des tumeurs. Ann Pathol 18: 103-9
19. Mousseau M, Schaerer R, Lutz JM, et al. (1991) Métastases hépatiques de site primitif inconnu. Bull Cancer 78: 725-36
20. Nissenblatt MI (1981) The CUP syndrome (carcinoma of unknown primary). Cancer Treat Rev 8: 211-24
21. Ordonez NG (2000) Thyroid transcription factor-I is a marker of lung and thyroid carcinomas. Adv Anat Pathol 7: 123-7
22. Tot T (2002) Cytokeratins 20 and 7 as biomarkers: usefulness in discrimining primary from metastatic adenocarcinoma. Eur J Cancer 38: 759-63
23. Voigt JJ (2001) Carcinomes de primitif inconnu. Ann Pathol, p. S99